# Elucid Bioimaging

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elucid-bioimaging

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: www.elucid.com
- Total disclosed funding: $90M
- Latest round: Series D (Sep 2, 2026)
- Investors on record: 11

## About

Based in Massachusetts, US, and founded in 2013, Elucid Bioimaging Inc. is a medical technology company that develops AI-powered cardiovascular imaging software. Marc Manley serves as Founder and Executive Chairman, while Kelly Huang serves as CEO. In September 2026, the company raised USD 55 million in Series D funding IAG Capital Partners and Elevage Medical Technologies.

Elucid uses machine learning and historical data to diagnose and treat cardiovascular disease accurately. The company’s product is ElucidVivo with PlaqueIQTM Technology includes image analysis software that employs CT angiography and patented computer algorithms based on histological data which is to find the actual position of arterial plaque to create personalized patient care.
The software works with all CTA Scanners using standard acquisition protocols and sensitive patient data is protected. The software uses an electronic medical recorder (EMR) and picture archiving and communication system (PACS) for timely clinical decision-making. Elucid also provides a software named ElucidVivo™ Clinical Research for clinical research and studies.

The company will use the September 2026 funding to accelerate commercial expansion of its clinical platform, support commercialization of FFR-CT and Plaque-IQ, continue artificial intelligence research and development, and advance landmark clinical studies.

## Funding rounds

- Series D, Sep 2, 2026, $55M — IAG Capital Partners, Elevage Medical Technologies, LP
- Series B, Jun 22, 2022, $27M — Bluestone Venture Partners, IAG Capital Partners, MedTex Ventures, Bold Brain Ventures, Biovision Ventures
- Series A, May 10, 2021, $8M — Bluestone Venture Partners, Checkmate Capital, Global Health Impact Funds, IAG Capital Partners, Angel Physicians Fund, Wolverine Venture Fund, MedTex Ventures, Willamette Valley Capital

## Investors

- Bluestone Venture Partners (https://capitalatlas.ai/funds/bluestone-venture-partners) — Series A, Series B
- Checkmate Capital (https://capitalatlas.ai/funds/checkmate-capital) — Series A
- Global Health Impact Funds (https://capitalatlas.ai/funds/global-health-impact-funds) — Series A
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Series A, Series B, Series D
- Angel Physicians Fund (https://capitalatlas.ai/funds/angel-physicians-fund) — Series A
- Wolverine Venture Fund (https://capitalatlas.ai/funds/wolverine-venture-fund) — Series A
- MedTex Ventures (https://capitalatlas.ai/funds/medtex-ventures) — Series A, Series B
- Willamette Valley Capital (https://capitalatlas.ai/funds/willamette-valley-capital) — Series A
- Bold Brain Ventures (https://capitalatlas.ai/funds/bold-brain-ventures) — Series B
- Biovision Ventures (https://capitalatlas.ai/funds/biovision-ventures) — Series B
- Elevage Medical Technologies, LP — Series D